Cyprotex Adds to Toxicology Services

Cyprotex PLC, a preclinical ADME Tox services company has launched a new in vitro toxicology service, branded as Cyprotox®. Supporting the new service is an additional 90 square metres of laboratory space at Cyprotex’s Macclesfield, UK facility, which offers multi-parametric automated fluorescent imaging and cellular analysis. The new facility utilises high content screening (HCS) technology and a range of other services to assess toxicity to determine multiparametric indicators of toxicity. HCS is a recent breakthrough for early toxicology assessment. It has been extensively validated, and is now being adopted throughout the pharmaceutical industry.

Dr Anthony Baxter, Chief Executive Officer, said: “Drug toxicity, and drug-induced liver injury in particular, is a major reason for failures in clinical trials and for the withdrawal of previously approved drugs from the market. Toxicity is the most costly problem in drug development today. Identifying potential liabilities at an early stage in drug discovery decreases the likelihood of latestage failures, and promises to produce the same magnitude of drug development efficiency improvements that preclinical ADME has provided. Cyprotex’s new toxicology facility complements our existing ADME business, and it aligns the capabilities of our UK facility with those of Apredica’s US facility, which Cyprotex acquired earlier this month.”